# SL-28 for Advanced Solid Tumours

Source: https://onco.cc/trials/nct07341737/  
OnCo record `nct07341737` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SL-28 in pancreatic ductal adenocarcinoma, non-small-cell lung cancer, oesophageal cancer, gastric & gastro-oesophageal junction cancer, hepatocellular carcinoma and bladder & urothelial cancer, run by Second Life Therapeutics, now recruiting.

## Summary

SL-28 for Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT07341737 by Second Life Therapeutics, with 60 participants planned, started 2026-08-14 and due to reach its primary completion in 2027-01-01. Interventions recorded: SL-28.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07341737
- Phase: 1/2
- Setting: A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours
- Sponsor: Second Life Therapeutics
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07341737: https://clinicaltrials.gov/study/NCT07341737

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct07341737.json